Historique
Bulletin de Périodique
Drug Testing and Analysis , Vol.6, n°7-8 - July-August 2014 - New psychoactive substances, part II
Auteur(s) :
S. D. BRANDT, Éditeur scientifique
Paru le :
01/07/2014
Langue(s) :
Anglais
Note de contenu :
CONTENTS:
- The new drug phenomenon [Editorial]. Brandt S.D., King L.A., Evans-Brown M., p. 587-597.
- Identification of (2-aminopropyl)indole positional isomers in forensic samples. Scott K.R., Power J.D., McDermott S.D., O'Brien J.E., Talbot B.N., Barry M.G., et al., p. 598-606.
- 5-(2-Aminopropyl)indole (5-IT): a psychoactive substance used for recreational purposes is an inhibitor of human monoamine oxidase (MAO). Herraiz T., Brandt S.D., p. 607-613.
- From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Morris H., Wallach J., p. 614-632.
- Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues. Wallach J., Paoli G.D., Adejare A., Brandt S.D., p. 633-650.
- Discrimination of cathinone regioisomers, sold as 'legal highs', by Raman spectroscopy. Christie R., Horan E., Fox J., O'Donnell C., Byrne H.J., McDermott S., et al., p. 651-657.
- Characterization of synthetic routes to 'Bromo-DragonFLY' and benzodifuranyl isopropylamine homologues utilizing ketone intermediates. Part 1: Synthesis of ketone precursors. O'Connor R.E., Keating J.J., p. 658-667.
- The syntheses, characterization and in vitro metabolism of nitracaine, methoxypiperamide and mephtetramine. Power J.D., Scott K.R., Gardner E.A., Curran McAteer B.M., O'Brien J.E., Brehon M., et al., p. 668-675.
- Characterization of the pyrolysis products of methiopropamine. Bouso E.D., Gardner E.A., O'Brien J.E., Talbot B., Kavanagh P.V., p. 676-683.
- Characterization of a novel and potentially lethal designer drug (±)-cis-para-methyl-4-methylaminorex (4,4'-DMAR, or 'Serotoni'). Brandt S.D., Baumann M.H., Partilla J.S., Kavanagh P.V., Power J.D., Talbot B., et al., p. 684-695.
- An investigation of the stability of emerging new psychoactive substances. Soh Y.N.A., Elliott S., p. 696-704.
- Study of collision-induced dissociation of electrospray-generated protonated cathinones. Fornal E., p. 705-715.
- Cross-reactivity of designer drugs, including cathinone derivatives, in commercial enzyme-linked immunosorbent assays. Swortwood M.J., Hearn W.L., DeCaprio A.P., p. 716-727.
- Validation of the only commercially available immunoassay for synthetic cathinones in urine: Randox Drugs of Abuse V Biochip Array Technology. Ellefsen K.N., Anizan S., Castaneto M.S., Desrosiers N.A., Martin T.M., Klette K.L., et al., p. 728-738.
- Predicting the activity and toxicity of new psychoactive substances: a pharmaceutical industry perspective. Leach A.G., p. 739-745.
- The in vivo and in vitro metabolism and the detectability in urine of 3',4'-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC-MS and LC-MSn. Meyer M.R., Mauer S., Meyer G.M.J., Dinger J., Klein B., Westphal F., et al., p. 746-756.
- Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. Moosmann B., Bisel P., Auwärter V., p. 757-763.
- Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Poklis J.L., Nanco C.R., Troendle M.M., Wolf C.E., Poklis A., p. 764-769.
- Cathinones derivatives-related deaths as exemplified by two fatal cases involving methcathinone with 4-methylmethcathinone and 4-methylethcathinone. Rojek S., Kłys M., Maciów-Głąb M., Kula K., Strona M., p. 770-777.
- Kitchen chemistry: A scoping review of the diversionary use of pharmaceuticals for non-medicinal use and home production of drug solutions. Van Hout M.C., p. 778-787.
- DART-MS for rapid, preliminary screening of urine for DMAA. Lesiak A.D., Adams K.J., Domin M.A., Henck C., Shepard J.R.E., p. 788-796.
- Analysis of 1,3 dimethylamylamine concentrations in Geraniaceae, geranium oil and dietary supplements. Austin K.G., Travis J., Pace G., Lieberman H.R., p. 797-804.
- A methamphetamine analog (N,α-diethyl-phenylethylamine) identified in a mainstream dietary supplement. Cohen P.A., Travis J.C., Venhuis B.J., p. 805-807.
- New phenethylamines in Europe. King L.A., p. 808-818.
- New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon? Giné C.V., Espinosa I.F., Vilamala M.V., p. 819-824.
- Changes in patterns of injecting drug use in Hungary: a shift to synthetic cathinones. Péterfi A., Tarján A., Horváth G.C., Csesztregi T., Nyírády A., p. 825-831.
- Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan. Kikura-Hanajiri R., Kawamura N.U.M., Goda Y., p. 832-839.
- Monitoring drug markets in the Internet age and the evolution of drug monitoring systems in Australia. Burns L., Roxburgh A., Bruno R., Van Buskirk J., p. 840-845.
- The rise of new psychoactive substance use in Australia. Burns L., Roxburgh A., Matthews A., Bruno R., Lenton S., Van Buskirk J., p. 846-849.
- Using poisons information service data to assess the acute harms associated with novel psychoactive substances. Wood D.M., Hill S.L., Thomas S.H.L., Dargan P.I., p. 850-860.
- Optimization, validation, and the application of liquid chromatography-tandem mass spectrometry for the analysis of new drugs of abuse in wastewater. van Nuijs A.L.N., Gheorghe A., Jorens P.G., Maudens K., Neels H., Covaci A., p. 861-867.
- The interim regulated legal market for NPS ('legal high') products in New Zealand: The impact of new retail restrictions and product licensing. Wilkins C., p. 868-875.
- Current challenges and problems in the field of new psychoactive substances in Germany from a law enforcement perspective. Duffert A., p. 876-878.
- Drug laws and the 'derivative' problem. King L.A., Ujváry I., Brandt S.D., p. 879-883.
- New psychoactive substances legislation in Ireland - Perspectives from academia. Kavanagh P.V., Power J.D., p. 884-891.
- The new drug phenomenon [Editorial]. Brandt S.D., King L.A., Evans-Brown M., p. 587-597.
- Identification of (2-aminopropyl)indole positional isomers in forensic samples. Scott K.R., Power J.D., McDermott S.D., O'Brien J.E., Talbot B.N., Barry M.G., et al., p. 598-606.
- 5-(2-Aminopropyl)indole (5-IT): a psychoactive substance used for recreational purposes is an inhibitor of human monoamine oxidase (MAO). Herraiz T., Brandt S.D., p. 607-613.
- From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Morris H., Wallach J., p. 614-632.
- Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues. Wallach J., Paoli G.D., Adejare A., Brandt S.D., p. 633-650.
- Discrimination of cathinone regioisomers, sold as 'legal highs', by Raman spectroscopy. Christie R., Horan E., Fox J., O'Donnell C., Byrne H.J., McDermott S., et al., p. 651-657.
- Characterization of synthetic routes to 'Bromo-DragonFLY' and benzodifuranyl isopropylamine homologues utilizing ketone intermediates. Part 1: Synthesis of ketone precursors. O'Connor R.E., Keating J.J., p. 658-667.
- The syntheses, characterization and in vitro metabolism of nitracaine, methoxypiperamide and mephtetramine. Power J.D., Scott K.R., Gardner E.A., Curran McAteer B.M., O'Brien J.E., Brehon M., et al., p. 668-675.
- Characterization of the pyrolysis products of methiopropamine. Bouso E.D., Gardner E.A., O'Brien J.E., Talbot B., Kavanagh P.V., p. 676-683.
- Characterization of a novel and potentially lethal designer drug (±)-cis-para-methyl-4-methylaminorex (4,4'-DMAR, or 'Serotoni'). Brandt S.D., Baumann M.H., Partilla J.S., Kavanagh P.V., Power J.D., Talbot B., et al., p. 684-695.
- An investigation of the stability of emerging new psychoactive substances. Soh Y.N.A., Elliott S., p. 696-704.
- Study of collision-induced dissociation of electrospray-generated protonated cathinones. Fornal E., p. 705-715.
- Cross-reactivity of designer drugs, including cathinone derivatives, in commercial enzyme-linked immunosorbent assays. Swortwood M.J., Hearn W.L., DeCaprio A.P., p. 716-727.
- Validation of the only commercially available immunoassay for synthetic cathinones in urine: Randox Drugs of Abuse V Biochip Array Technology. Ellefsen K.N., Anizan S., Castaneto M.S., Desrosiers N.A., Martin T.M., Klette K.L., et al., p. 728-738.
- Predicting the activity and toxicity of new psychoactive substances: a pharmaceutical industry perspective. Leach A.G., p. 739-745.
- The in vivo and in vitro metabolism and the detectability in urine of 3',4'-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC-MS and LC-MSn. Meyer M.R., Mauer S., Meyer G.M.J., Dinger J., Klein B., Westphal F., et al., p. 746-756.
- Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. Moosmann B., Bisel P., Auwärter V., p. 757-763.
- Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Poklis J.L., Nanco C.R., Troendle M.M., Wolf C.E., Poklis A., p. 764-769.
- Cathinones derivatives-related deaths as exemplified by two fatal cases involving methcathinone with 4-methylmethcathinone and 4-methylethcathinone. Rojek S., Kłys M., Maciów-Głąb M., Kula K., Strona M., p. 770-777.
- Kitchen chemistry: A scoping review of the diversionary use of pharmaceuticals for non-medicinal use and home production of drug solutions. Van Hout M.C., p. 778-787.
- DART-MS for rapid, preliminary screening of urine for DMAA. Lesiak A.D., Adams K.J., Domin M.A., Henck C., Shepard J.R.E., p. 788-796.
- Analysis of 1,3 dimethylamylamine concentrations in Geraniaceae, geranium oil and dietary supplements. Austin K.G., Travis J., Pace G., Lieberman H.R., p. 797-804.
- A methamphetamine analog (N,α-diethyl-phenylethylamine) identified in a mainstream dietary supplement. Cohen P.A., Travis J.C., Venhuis B.J., p. 805-807.
- New phenethylamines in Europe. King L.A., p. 808-818.
- New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon? Giné C.V., Espinosa I.F., Vilamala M.V., p. 819-824.
- Changes in patterns of injecting drug use in Hungary: a shift to synthetic cathinones. Péterfi A., Tarján A., Horváth G.C., Csesztregi T., Nyírády A., p. 825-831.
- Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan. Kikura-Hanajiri R., Kawamura N.U.M., Goda Y., p. 832-839.
- Monitoring drug markets in the Internet age and the evolution of drug monitoring systems in Australia. Burns L., Roxburgh A., Bruno R., Van Buskirk J., p. 840-845.
- The rise of new psychoactive substance use in Australia. Burns L., Roxburgh A., Matthews A., Bruno R., Lenton S., Van Buskirk J., p. 846-849.
- Using poisons information service data to assess the acute harms associated with novel psychoactive substances. Wood D.M., Hill S.L., Thomas S.H.L., Dargan P.I., p. 850-860.
- Optimization, validation, and the application of liquid chromatography-tandem mass spectrometry for the analysis of new drugs of abuse in wastewater. van Nuijs A.L.N., Gheorghe A., Jorens P.G., Maudens K., Neels H., Covaci A., p. 861-867.
- The interim regulated legal market for NPS ('legal high') products in New Zealand: The impact of new retail restrictions and product licensing. Wilkins C., p. 868-875.
- Current challenges and problems in the field of new psychoactive substances in Germany from a law enforcement perspective. Duffert A., p. 876-878.
- Drug laws and the 'derivative' problem. King L.A., Ujváry I., Brandt S.D., p. 879-883.
- New psychoactive substances legislation in Ireland - Perspectives from academia. Kavanagh P.V., Power J.D., p. 884-891.
Exemplaires
| Disponibilité |
|---|
| aucun exemplaire |
Dépouillements
Ajouter le résultat à votre sélection
L. A. KING
|
2014
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
Sixteen phenethylamines are now included in Schedules I and II of the United Nations 1971 Convention on Psychotropic Substances. Most of the ring-substituted compounds are in Schedule I, whereas 2C-B, amphetamine, and methamphetamine are listed [...]
S. D. BRANDT ;
L. A. KING ;
M. EVANS-BROWN
|
2014
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
This special issue provides a multidisciplinary snapshot of recent developments of the broader, arguably phenomenal, changes to the drug market that have occurred in the past decade related to the rise of the new drug phenomenon. This change is [...]
H. MORRIS ;
J. WALLACH
|
2014
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
PCP or phencyclidine was discovered in 1956 and soon became a popular street drug. Dissociatives including PCP, ketamine, and dextromethorphan have been used non-medically for their mind-altering effects for over 60 years. Many of these compound[...]
M. C. VAN HOUT
|
2014
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
Misuse of pharmaceuticals is of increasing drug policy and public health concern. A scoping review was conducted on the diversionary use of pharmaceuticals for non-medicinal use and home production of drug solutions. The research question was br[...]
C. VIDAL-GINÉ ;
I. FORNIS ESPINOSA ;
M. VENTURA VILAMALA
|
2014
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
The use of new psychoactive substances (NPS) as adulterants has received little attention in the literature. In this paper, results from Energy Control's drug checking service documenting the use of NPS as adulterants of controlled drugs are pre[...]
A. PÉTERFI ;
A. TARJAN ;
G. HORVATH ;
T. CSESZTREGI ;
A. NYIRADY
|
2014
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
The spread of synthetic cathinone injecting is a new phenomenon observed in recent years in Hungary. Until 2010, when the first anecdotal reports on cathinone injecting appeared, injecting was associated with the use of heroin and amphetamine. I[...]
R. KIKURA-HANAJIRI ;
N. KAWAMURA ;
M. UCHIYAMA ;
Y. GODA
|
2014
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
To counter the spread of the many analogues of psychoactive substances, the Pharmaceutical Affairs Law in Japan was amended in 2006 to establish a new category - Designated Substances - in order to more promptly control these drugs. As of March [...]
L. BURNS ;
A. ROXBURGH ;
R. BRUNO ;
J. VAN BUSKIRK
|
2014
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
In Australia, drug monitoring systems have been in place for more than a decade allowing for the measurement of ongoing trends in drug use and the detection of new drugs. The Drug Trends Unit at the National Drug and Alcohol Research Centre moni[...]
L. BURNS ;
A. ROXBURGH ;
A. MATTHEWS ;
R. BRUNO ;
S. LENTON ;
J. VAN BUSKIRK
|
2014
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
New Psychoactive Substances are now a feature of Australia's recreational drug market. Little is known, however, about the prevalence of use, the characteristics of people who use them and the relationship between the NPS and ecstasy markets. Th[...]
D. M. WOOD ;
S. L. HILL ;
S. H. L. THOMAS ;
P. I. DARGAN
|
2014
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
Novel psychoactive substances (NPS) can cause significant acute toxicity but usually little is known about their toxicity when they enter the recreational drug scene. Current data sources include online user forums, user questionnaires, case rep[...]
C. WILKINS
|
2014
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
New Zealand has recently established the world's first regulated legal market for new psychoactive products (NPS) (i.e. ‘legal highs’). While the new regime is currently in a transitional phase, a range of retail restrictions and an interim lice[...]
A. DUFFERT
|
2014
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
Over the last few years, a range of so-called new psychoactive substances (NPS) have established themselves on the German recreational drug scene, causing increased concern. At the same time, a great number of Internet shops have come into exist[...]
L. A. KING ;
I. UJVARY ;
S. D. BRANDT
|
2014
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
The concept of a 'derivative' is used widely in chemistry, where its precise meaning depends on the circumstances. However, numerous examples of derivative also occur in domestic drugs legislation, some of which stem from the 1961 United Nations[...]
P. V. KAVANAGH ;
J. D. POWER
|
2014
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
Dans Drug Testing and Analysis (Vol.6, n°7-8, July-August 2014) Article : Périodique
The emergence of ‘legal highs’ or ‘new psychoactive substances’ (NPS) on the Irish market is reflective of their appearance in many countries, with some notable exceptions. The official response to the situation is examined here by looking at Ir[...]